Highest-materiality recent filing
Pro-Dex extends Irvine lease to Sept 2030 with escalating base rent
Lease term extended to September 30, 2030; amendment effective August 18, 2026.
Pro-Dex Q4 net income up 142% to $2.9M; FY26 sales up 16% to $77.5M
Q4 net sales $20.4M, up 17% YoY; gross margin 35% vs 20% prior year.
Pro-Dex awards $200K in discretionary bonuses to CEO and CFO for FY2026 outperformance
CEO Richard L. Van Kirk receives $140,000 discretionary bonus for fiscal 2026 sales growth and performance exceeding plan.
Pro-Dex begins investor presentations; no financial details in filing text
Filed Form 8-K on June 17, 2026 under Item 7.01 for Regulation FD disclosure.
Pro-Dex Q3 revenue record $19.9M; net income up to $3.9M on one-time gain
Q3 net sales record $19.9M, up 15% YoY; driven by $4.7M increase in largest customer's next-gen handpiece.
Pro-Dex increases CFO Alisha Charlton's base salary to $257,000
Base salary raised from $247,200 to $257,000 per year (approx. 4% increase).
Pro-Dex acquires Advanced Precision Machining for $8.65M; finances with UMB term loan
Total purchase price ~$8.65M: $6.65M cash at closing (funded by UMB Term Note D) + $2M subordinated note (8% interest, 63 months).
Pro-Dex Q2 sales up 11% to $18.7M; net income $0.66/share; eyes acquisition of supplier
Net sales $18.7M (+11% YoY) driven by $7.3M in next-gen orthopedic handpiece shipments offset by legacy declines.
Pro-Dex extends largest customer contract through 2028, grants CEO $225K bonus
Executed three-year contract amendment with largest customer, extending through Dec 31, 2028.
Compensation committee granted 1,000 restricted shares to CFO Alisha K. Charlton, vesting over five years.
Pro-Dex Q1 FY2026: sales +24% to $18.5M, EPS $1.40 incl. $3.3M unrealized gains
Net sales rose 24% YoY to $18.5M driven by resumed next-generation handpiece production for largest customer.
Full-year net sales $66.6M (+24% YoY), operating income $10.7M (+49%), net income $9.0M ($2.67 diluted EPS) vs $2.1M ($0.60).
Pro-Dex awards $120k in discretionary bonuses to CEO and CFO
CEO Richard Van Kirk receives $70k bonus for sales growth and FY2025 performance exceeding plan.
Pro-Dex changes auditor to Baker Tilly after Moss Adams merger
Moss Adams merged into Baker Tilly effective June 3, 2025; Baker Tilly appointed as successor independent auditor.
Pro-Dex Q3 net income $3.3M ($0.98/share), sales up 22% to $17.4M
Net sales rose 22% to $17.4M driven by $6.2M of next-gen orthopedic handpiece shipments.
Pro-Dex increases revolving credit line from $7M to $11M with UMB Bank
Revolving credit line raised to $11M (from $7M); $5M drawn and outstanding as of April 8, 2025.
Pro-Dex Q2 net sales up 33% to $16.8M; EPS $0.61 vs $0.14
Q2 net sales $16.8M (+33% YoY) driven by $3.1M shipment of next-gen orthopedic handpiece for largest customer.
Pro-Dex extends $7M revolving credit facility maturity to Dec 2026
Maturity extended from December 29, 2025 to December 29, 2026.
Pro-Dex grants restricted shares to CEO, CFO, directors, and employees under 2016 Plan
Compensation Committee approved restricted share grants on Nov 20, 2024 to non-employee directors and select employees.
All seven director nominees elected with 2.0M-2.3M votes for each; broker non-votes of 542,256.
Pro-Dex Q1 net sales up 25% to $14.9M; net income $2.5M vs loss prior year
Net sales $14.9M (+25% YoY); gross margin 35% (+4pp); operating income $3.0M (+64%).
Pro-Dex CEO awarded $70,000 discretionary bonus for Q1 FY2025 performance
Compensation Committee approved $70,000 discretionary cash bonus for CEO Richard L. Van Kirk.
Q4 net sales $15.0M (+41% YoY); operating income $2.4M (+46%); diluted EPS $0.46 vs $0.42.
Pro-Dex awards $120K in discretionary bonuses to CEO and CFO for FY2024 performance
CEO Richard L. Van Kirk receives $70,000 cash bonus based on sales growth and FY2024 financial performance exceeding plan.
Pro-Dex enters $5M Term Loan C to refinance revolving debt and fund stock buybacks
New $5M Term Loan C refinances $3M revolving balance; $2M+ available for stock repurchases under 10b5-1 plan.
Pro-Dex Q3 revenue up 9% to $14.3M; net income falls to $0.19 EPS on investment losses
Net sales $14.3M (+9% YoY); operating income $2.2M (+7%) driven by medical device revenue.
Net sales increased 12% to $12.6M vs $11.3M a year ago; repair revenue from orthopedic surgical handpiece drove growth.
Pro-Dex CEO salary raised to $350K; new bonus plan with target range $75K-$300K
CEO Richard L. Van Kirk's base salary increased from $305,000 to $350,000 per year, effective next bi-weekly pay period.
Pro-Dex extends credit facility maturity to December 2025, $2.5M drawn
Maturity of revolving and supplemental notes extended from Dec 2024 to Dec 29, 2025.
Pro-Dex shareholders elect all seven director nominees and ratify auditor at 2023 Annual Meeting
All seven director nominees elected with 2,201,619 to 2,271,327 votes for; broker non-votes 639,427.
Net loss of $615k ($0.17 diluted) vs net income of $1.2M ($0.33) in prior-year quarter.
Pro-Dex raises CFO Alisha Charlton's salary to $247,200; grants 2,000 performance shares
CFO Alisha K. Charlton's base salary increased from $240,000 to $247,200, effective next bi-weekly pay period.
Pro-Dex Q4 revenue down 16% YoY; full-year net income up 54% on record backlog $41.6M
Q4 net sales fell 16% YoY to $10.6M; net income down $336K to $1.5M ($0.42 diluted EPS) vs $0.49 last year.
Company will restate audited FY2020-2022 and unaudited interim quarters through Mar 2023; prior reports no longer reliable.
CEO Richard L. Van Kirk awarded $70,000 discretionary bonus based on sales growth and fiscal 2023 performance exceeding plan.
Pro-Dex Q3 net sales up 41% to $13.1M, net income $1.3M vs $462K
Net sales $13.1M (+41% YoY), driven by $3.2M repair revenue from enhanced handpiece program.
Pro-Dex Q2 revenue up 11% to $11.3M; net income dips to $879K from $925K
Q2 net sales $11.3M (+11% YoY); net income $879K ($0.24 diluted EPS) vs $925K ($0.25) last year.
Pro-Dex expands credit facilities to $10M, extends maturity to Dec 2024
Revolving line increased from $2M to $7M; maturity extended from Nov 2023 to Dec 29, 2024.
Pro-Dex shareholders elect all 7 director nominees, ratify auditor, approve advisory say-on-pay
All seven director nominees elected; votes ranged from 2,148,695 (Swenson) to 2,262,099 (Hovda); broker non-votes 690,890.
Pro-Dex Q1 revenue up 11% to $11.1M; EPS flat at $0.29; gross margin drops 7 pts
Net sales $11.1M (+11% YoY); net income $1.1M ($0.29 diluted EPS) vs $1.1M ($0.28) prior year.
Pro-Dex Q4 revenue up 34% to $12.6M; full-year net income $3.9M
Q4 net sales $12.6M (+34% YoY); net income $1.4M ($0.38/diluted) vs $0.8M ($0.20) in Q4 FY21.
Pro-Dex awards $130K in discretionary bonuses to CEO and CFO
Compensation Committee approved $70K discretionary bonus for CEO Richard L. Van Kirk based on sales growth.
Pro-Dex Q3 net sales down 21% to $9.3M; EPS $0.12 vs $0.54 YoY
Net sales $9.3M, down $2.5M (21%) from $11.7M due to thoracic driver launch completion.
Pro-Dex Q2 net sales up 23% to $10.2M but net income falls to $0.25 EPS from $0.44
Q2 net sales $10.2M (+23% YoY) driven by orthopedic surgical handpiece sales to largest customer.
Pro-Dex CFO gets base salary raise to $240K, re-allocated forfeited equity awards
CFO Alisha Charlton's base salary increased from $225,000 to $240,000, effective next bi-weekly pay period.
Pro-Dex appoints Angelita Domingo to board, expanding board from 6 to 7 members
Board increased from six to seven members; Angelita Domingo appointed as director effective Dec 20, 2021.
Pro-Dex shareholders reelect all six directors, ratify auditor, approve say-on-pay
All six director nominees elected; votes for ranged from 1,320,329 to 1,403,589.
Pro-Dex Q1 net sales $10.0M (+16% YoY); diluted EPS $0.28 vs $0.29
Net sales $10.0M for Q1 FY2022 ended Sep 30, 2021, up 16% from $8.6M a year ago.
Pro-Dex extends $2M revolving credit facility maturity to Nov 2023, reduces rate
Maturity of $2M revolving credit note extended from Nov 5, 2021 to Nov 5, 2023.
Pro-Dex awards CEO Richard Van Kirk $70,000 discretionary performance bonus
Compensation Committee approved $70,000 bonus for CEO Richard L. Van Kirk on Aug 31, 2021.
the Board appointed Angelita (“Angel”) Domingo, age 49, as a director in order to fill the newly created vacancy due to the expansion of the size of the Board, effective as of December 20, 2021.
Max materiality 0.85 · Median 0.57 · Most common event earnings